{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:37Z","timestamp":1791520837003,"version":"4.3.4"},"reference-count":54,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary aldosteronism (PA) is a condition that is still largely overlooked, resulting in a considerable burden of mortality and morbidity. This is despite decades of clinical and translational research on the deleterious effects of aldosterone on the cardiovascular system and the publication of several guidelines and consensuses on its diagnosis and treatment. One of the main reasons for the low rate of testing is the difficulty of screening patients on antihypertensive therapy that potentially interferes with aldosterone and renin levels and thus confound the interpretation of the aldosterone to renin ratio, the accepted and conventionally used screening test. To avoid interference, usually the therapies that affect the renin-angiotensin aldosterone system are withdrawn and substituted with noninterfering medications. However, in many cases the screening test can be confidently interpreted even when such therapies are not discontinued. In this review, we will evaluate the effects of antihypertensive therapies on the screening test for PA and suggest a practical approach for its interpretation.<\/jats:p>","DOI":"10.1210\/clinem\/dgac460","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T03:27:42Z","timestamp":1660447662000},"page":"3175-3181","source":"Crossref","is-referenced-by-count":35,"title":["Approach to the Patient on Antihypertensive Therapy: Screen for Primary Aldosteronism"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5480-1116","authenticated-orcid":false,"given":"Paolo","family":"Mulatero","sequence":"first","affiliation":[{"name":"Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino , 10126, Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bertello","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino , 10126, Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-6890","authenticated-orcid":false,"given":"Franco","family":"Veglio","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino , 10126, Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-2005","authenticated-orcid":false,"given":"Silvia","family":"Monticone","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino , 10126, Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"issue":"10","key":"2022112301500256600_CIT0001","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens."},{"issue":"5","key":"2022112301500256600_CIT0002","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2022112301500256600_CIT0003","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"2022112301500256600_CIT0004","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2022112301500256600_CIT0005","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens."},{"issue":"14","key":"2022112301500256600_CIT0006","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"16","key":"2022112301500256600_CIT0007","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"2022112301500256600_CIT0008","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol."},{"issue":"9","key":"2022112301500256600_CIT0009","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.ej11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism\u2014the Japan Endocrine Society 2009","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr J."},{"issue":"14","key":"2022112301500256600_CIT0010","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jacc.2017.02.041","article-title":"The time has come for systematic screening for primary aldosteronism in all hypertensives","volume":"69","author":"Maiolino","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"2022112301500256600_CIT0011","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022112301500256600_CIT0012","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","article-title":"Guidelines for primary aldosteronism: uptake by primary care physicians in Europe","volume":"34","author":"Mulatero","year":"2016","journal-title":"J Hypertens."},{"issue":"3","key":"2022112301500256600_CIT0013","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med."},{"issue":"9","key":"2022112301500256600_CIT0014","doi-asserted-by":"publisher","first-page":"e3603","DOI":"10.1210\/clinem\/dgab327","article-title":"Increasing incidence of primary aldosteronism in Western Sweden during 3 decades\u2014yet an underdiagnosed disorder","volume":"106","author":"Gkaniatsa","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112301500256600_CIT0015","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.surg.2019.05.087","article-title":"Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system","volume":"167","author":"Sivarajah","year":"2020","journal-title":"Surgery."},{"issue":"6","key":"2022112301500256600_CIT0016","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","article-title":"Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism","volume":"156","author":"Liu","year":"2021","journal-title":"JAMA Surg."},{"issue":"1","key":"2022112301500256600_CIT0017","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension."},{"issue":"4","key":"2022112301500256600_CIT0018","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension."},{"issue":"10060","key":"2022112301500256600_CIT0019","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","article-title":"A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension","volume":"388","author":"Olsen","year":"2016","journal-title":"Lancet."},{"issue":"5","key":"2022112301500256600_CIT0020","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/HJH.0000000000001088","article-title":"Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism","volume":"34","author":"Burrello","year":"2016","journal-title":"J Hypertens."},{"issue":"12","key":"2022112301500256600_CIT0021","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1097\/HJH.0000000000000727","article-title":"Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays","volume":"33","author":"Manolopoulou","year":"2015","journal-title":"J Hypertens."},{"issue":"9","key":"2022112301500256600_CIT0022","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1515\/cclm-2015-1094","article-title":"Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension","volume":"54","author":"Rossi","year":"2016","journal-title":"Clin Chem Lab Med."},{"issue":"1","key":"2022112301500256600_CIT0023","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/HYPERTENSIONAHA.117.10197","article-title":"Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study","volume":"71","author":"Song","year":"2018","journal-title":"Hypertension."},{"issue":"5","key":"2022112301500256600_CIT0024","doi-asserted-by":"publisher","first-page":"e005574","DOI":"10.1161\/JAHA.117.005574","article-title":"Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: the Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) study","volume":"6","author":"Maiolino","year":"2017","journal-title":"J Am Heart Assoc."},{"issue":"2","key":"2022112301500256600_CIT0025","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med."},{"issue":"12","key":"2022112301500256600_CIT0026","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1055\/s-0043-121468","article-title":"Can screening and confirmatory testing in the management of patients with primary aldosteronism be improved?","volume":"49","author":"Stowasser","year":"2017","journal-title":"Horm Metab Res."},{"issue":"12","key":"2022112301500256600_CIT0027","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2022112301500256600_CIT0028","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1161\/HYPERTENSIONAHA.121.17444","article-title":"Clinical score and machine learning-based model to predict diagnosis of primary aldosteronism in arterial hypertension","volume":"78","author":"Buffolo","year":"2021","journal-title":"Hypertension."},{"issue":"2","key":"2022112301500256600_CIT0029","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/er.2017-00054","article-title":"Screening for endocrine hypertension: an Endocrine Society scientific statement","volume":"38","author":"Young","year":"2017","journal-title":"Endocr Rev."},{"issue":"3","key":"2022112301500256600_CIT0030","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1055\/s-0031-1295460","article-title":"Factors affecting the aldosterone\/renin ratio","volume":"44","author":"Stowasser","year":"2012","journal-title":"Horm Metab Res."},{"issue":"1","key":"2022112301500256600_CIT0031","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","article-title":"International histopathology consensus for unilateral primary aldosteronism","volume":"106","author":"Williams","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022112301500256600_CIT0032","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2022112301500256600_CIT0033","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.hyp.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension."},{"issue":"7","key":"2022112301500256600_CIT0034","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1210\/jc.2010-0225","article-title":"Effect of atenolol on aldosterone\/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers","volume":"95","author":"Ahmed","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112301500256600_CIT0035","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2016-3821","article-title":"Effect of moxonidine on the aldosterone\/renin ratio in healthy male volunteers","volume":"102","author":"Ahmed","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112301500256600_CIT0036","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1161\/HYPERTENSIONAHA.119.13772","article-title":"Renin-angiotensin-aldosterone system Triple-A analysis for the screening of primary aldosteronism","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension."},{"issue":"2","key":"2022112301500256600_CIT0037","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","article-title":"Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin II ratio in patients with primary aldosteronism","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension."},{"issue":"9","key":"2022112301500256600_CIT0038","doi-asserted-by":"publisher","first-page":"e3655","DOI":"10.1210\/clinem\/dgab290","article-title":"Mineralocorticoid receptor antagonist effect on aldosterone to renin ratio in patients with primary aldosteronism","volume":"106","author":"Pecori","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022112301500256600_CIT0039","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/jc.2014-2788","article-title":"Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy","volume":"99","author":"Haase","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112301500256600_CIT0040","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/jc.2018-01299","article-title":"Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism","volume":"104","author":"Nanba","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112301500256600_CIT0041","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1210\/clinem\/dgaa080","article-title":"Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism\u2014the EMIRA study","volume":"105","author":"Rossi","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022112301500256600_CIT0042","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1097\/01.hjh.0000187260.32567.75","article-title":"Primary hyperaldosteronism: a frequent cause of residual hypertension after successful endovascular treatment of renal artery disease","volume":"23","author":"Pizzolo","year":"2005","journal-title":"J Hypertens."},{"issue":"11","key":"2022112301500256600_CIT0043","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrendo.2012.155","article-title":"Adrenal disorders in pregnancy","volume":"8","author":"Monticone","year":"2012","journal-title":"Nat Rev Endocrinol."},{"key":"2022112301500256600_CIT0044","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09729-6","article-title":"Primary aldosteronism in pregnancy","author":"Forestiero","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"7","key":"2022112301500256600_CIT0045","doi-asserted-by":"crossref","first-page":"e2320","DOI":"10.1210\/clinem\/dgaa206","article-title":"Primary aldosteronism in the elderly","volume":"105","author":"Mulatero","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112301500256600_CIT0046","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/HYPERTENSIONAHA.113.02187","article-title":"Pseudohypoaldosteronism type II: history, arguments, answers, and still some questions","volume":"63","author":"Healy","year":"2014","journal-title":"Hypertension."},{"issue":"4","key":"2022112301500256600_CIT0047","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.beem.2020.101399","article-title":"Diagnostic approach to low-renin hypertension","volume":"89","author":"Monticone","year":"2018","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"10","key":"2022112301500256600_CIT0048","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.ekir.2021.07.025","article-title":"The variety of genetic defects explains the phenotypic heterogeneity of familial hyperkalemic hypertension","volume":"6","author":"Hureaux","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"6","key":"2022112301500256600_CIT0049","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1210\/jc.2010-2918","article-title":"Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022112301500256600_CIT0050","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1210\/jc.2016-3851","article-title":"Effect of combined hormonal replacement therapy on the aldosterone\/renin ratio in postmenopausal women","volume":"102","author":"Ahmed","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112301500256600_CIT0051","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.1210\/jc.2010-1355","article-title":"Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022112301500256600_CIT0052","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0002-9343(90)90344-d","article-title":"Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis","volume":"89","author":"Eriksson","year":"1990","journal-title":"Am J Med."},{"issue":"1","key":"2022112301500256600_CIT0053","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"2022112301500256600_CIT0054","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1097\/HJH.0000000000002520","article-title":"Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac460\/45417667\/dgac460.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/11\/3175\/47201310\/dgac460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/11\/3175\/47201310\/dgac460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:51:22Z","timestamp":1669168282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/11\/3175\/6665972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,8,13]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac460","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,13]]}}}